BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6555016)

  • 1. Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci.
    Lowy FD; Chang DS; Lash PR
    Antimicrob Agents Chemother; 1983 Jun; 23(6):932-4. PubMed ID: 6555016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between rifampin and fusidic acid against methicillin-resistant coagulase-positive and -negative staphylococci.
    Farber BF; Yee YC; Karchmer AW
    Antimicrob Agents Chemother; 1986 Jul; 30(1):174-5. PubMed ID: 3638931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase-negative staphylococci by time-kill method.
    Thamlikitkul V
    J Med Assoc Thai; 1991 Dec; 74(12):669-74. PubMed ID: 1839906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.
    Watanakunakorn C; Tisone JC
    Antimicrob Agents Chemother; 1982 Nov; 22(5):903-5. PubMed ID: 6924825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro effects of vancomycin and rifampicin, alone and in combination, against methicillin-sensitive and methicillin-resistant staphylococci.
    Varaldo PE; Debbia E; Schito GC
    J Antimicrob Chemother; 1984 Dec; 14 Suppl D():35-41. PubMed ID: 6569872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus.
    Bayer AS; Morrison JO
    Antimicrob Agents Chemother; 1984 Aug; 26(2):220-3. PubMed ID: 6567464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility and synergy studies of methicillin-resistant Staphylococcus epidermidis.
    Ein ME; Smith NJ; Aruffo JF; Heerema MS; Bradshaw MW; Williams TW
    Antimicrob Agents Chemother; 1979 Nov; 16(5):655-9. PubMed ID: 260880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci.
    Goldstein FW; Coutrot A; Sieffer A; Acar JF
    Antimicrob Agents Chemother; 1990 May; 34(5):899-900. PubMed ID: 2141780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditis.
    Brandt CM; Rouse MS; Tallan BM; Laue NW; Wilson WR; Steckelberg JM
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1815-9. PubMed ID: 7486924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New trends in the chemotherapy of staphylococcal infections.
    Russo G; Tempera G; Stefani S; Nicoletti G
    Chemioterapia; 1986 Apr; 5(2):116-9. PubMed ID: 3635440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus.
    Mulazimoglu L; Drenning SD; Muder RR
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1534-5. PubMed ID: 8726033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci.
    Domaracki BE; Evans AM; Venezia RA
    Antimicrob Agents Chemother; 2000 May; 44(5):1394-6. PubMed ID: 10770789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer agents against methicillin and/or gentamicin-resistant and -susceptible staphylococci.
    Chandrasekar PH; Sluchak JA
    Chemotherapy; 1989; 35(5):333-7. PubMed ID: 2551600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species.
    Varaldo PE; Debbia E; Schito GC
    Antimicrob Agents Chemother; 1985 Apr; 27(4):615-8. PubMed ID: 3847272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: an in-vitro comparison with vancomycin plus rifampicin.
    Walsh TJ; Auger F; Tatem BA; Hansen SL; Standiford HC
    J Antimicrob Chemother; 1986 Jan; 17(1):75-82. PubMed ID: 3633267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sensitivity of methicillin-resistant Staphylococcus aureus to vancomycin, gentamicin and pristinamycin].
    Yourassowsky E; Schoutens E
    Acta Clin Belg; 1971; 26(3):139-45. PubMed ID: 5211728
    [No Abstract]   [Full Text] [Related]  

  • 17. In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus.
    Foldes M; Munro R; Sorrell TC; Shanker S; Toohey M
    J Antimicrob Chemother; 1983 Jan; 11(1):21-6. PubMed ID: 6826485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus species.
    Rohner P; Herter C; Auckenthaler R; Pechère JC; Waldvogel FA; Lew DP
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2037-41. PubMed ID: 2619272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.
    Grohs P; Kitzis MD; Gutmann L
    Antimicrob Agents Chemother; 2003 Jan; 47(1):418-20. PubMed ID: 12499229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of teicoplanin alone and in combination with rifampicin, gentamicin or tobramycin against coagulase-negative staphylococci.
    Watanakunakorn C
    J Antimicrob Chemother; 1987 Apr; 19(4):439-43. PubMed ID: 2953706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.